CAR-T cell therapy: MS Clinical Trials
4 active trials · 4 recruiting
4 active multiple sclerosis clinical trials involve CAR-T cell therapy, 4 currently recruiting. The list is matched on the interventions registered at ClinicalTrials.gov, so it includes head-to-head comparisons and studies where this therapy is the comparator as well as the treatment under test.
Trial results are not treatment advice: whether a therapy is right for you depends on your type of MS, disease activity and history, which is a conversation for your neurologist.
Active CAR-T cell therapy MS trials
RecruitingPhase 1
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Sponsor: Stanford University
KYV-101 anti-CD19 CAR-T cell therapy · Standard lymphodepletion regimen
1 state12 participantsDetails ›
RecruitingPhase 1
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Sponsor: Daishi Tian
CD19/BCMA-targeted CAR-T cells · Lymphodepleting Conditioning
36 participantsDetails ›
RecruitingPhase 1
This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis
Sponsor: Daishi Tian
GC012F CAR-T Cell Injection
15 participantsDetails ›
RecruitingPhase 1
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Sponsor: RenJi Hospital
CD20/BCMA-directed CAR-T cells
30 participantsDetails ›
MS trials by therapy
Exercise and rehabilitation (81)Ocrelizumab (Ocrevus) (34)Ofatumumab (Kesimpta) (18)Diet and nutrition (12)Teriflunomide (Aubagio) (9)Fingolimod (Gilenya) (8)Ublituximab (Briumvi) (7)Cladribine (Mavenclad) (7)Rituximab (6)Ozanimod (Zeposia) (6)Dimethyl fumarate (Tecfidera) (6)Interferon beta (5)Fenebrutinib (5)Stem cell therapy (aHSCT and MSC) (5)Natalizumab (Tysabri) (4)Siponimod (Mayzent) (4)Remibrutinib (4)Alemtuzumab (Lemtrada) (3)Glatiramer acetate (Copaxone) (3)Frexalimab (3)Metformin (3)Cannabis and cannabinoids (3)
